VKORC1 variant genotypes influence warfarin response in patients undergoing total joint arthroplasty: A pilot study

Clinical Orthopaedics and Related Research

Volumn 467, Issue 7, 2009, Pages 1773-1780

  González Della Valle, Alejandro ^a   Khakharia, Saurabh ^a   Glueck, Charles J ^b   Taveras, Nicole ^a   Wang, Ping ^b   Fontaine, Robert N ^c   Salvati, Eduardo A ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b JEWISH HOSPITAL   (United States)

^c Molecular Diagnostics Laboratory   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COAGULATING AGENT; HEPARIN; MENADIONE EPOXIDE; OXIDOREDUCTASE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE; WARFARIN; ANTICOAGULANT AGENT; MENADIONE EPOXIDASE; MIXED FUNCTION OXIDASE;

ADULT; AGED; ANTICOAGULATION; ARTHROPLASTY; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HIGH RISK PATIENT; HOMOZYGOTE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MUTANT; PATIENT IDENTIFICATION; PHARMACOGENETICS; PHARMACOGENOMICS; POSTOPERATIVE PERIOD; POSTOPERATIVE THROMBOSIS; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RISK ASSESSMENT; DRUG RESISTANCE; GENETICS; HIP ARTHROPLASTY; KNEE ARTHROPLASTY; MIDDLE AGED; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; DRUG RESISTANCE; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOSIS; WARFARIN;

EID: 67649783974     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1007/s11999-008-0641-5     Document Type: Article

References (43)

1. HC Amstutz DA Friscia F Dorey BT Carney 1989 Warfarin prophylaxis to prevent mortality from pulmonary embolism after total hip replacement J Bone Joint Surg Am. 71 321 326 2784442 1:STN:280:DyaL1M7nsVymsw%3D%3D
2. PD Asnis MJ Gardner A Ranawat AH Leitzes MG Peterson AR Bass 2007 The effectiveness of warfarin dosing from a nomogram compared with house staff dosing J Arthroplasty. 22 213 218 17275636 10.1016/j.arth.2006.03.006 (Pubitemid 46162081)
3. B Beksac A Gonzalez Della Valle J Anderson NE Sharrock TP Sculco EA Salvati 2007 Symptomatic thromboembolism after one-stage bilateral THA with a multimodal prophylaxis protocol Clin Orthop Relat Res. 463 114 119 17960674
4. B Beksac A Gonzalez Della Valle EA Salvati 2006 Thromboembolic disease after total hip arthroplasty: who is at risk? Clin Orthop Relat Res. 453 211 224 17006373 10.1097/01.blo.0000238848.41670.41 (Pubitemid 44900986)
5. AJ Butt T McCarthy IP Kelly T Glynn G McCoy 2005 Sciatic nerve palsy secondary to postoperative haematoma in primary total hip replacement J Bone Joint Surg Br. 87 1465 1467 16260659 10.1302/0301-620X.87B11.16736 1:STN:280:DC%2BD2Mrot1OisA%3D%3D (Pubitemid 41723085)
6. JA Caprini JI Arcelus G Motykie JC Kudrna D Mokhtee JJ Reyna 1999 The influence of oral anticoagulation therapy on deep vein thrombosis rates four weeks after total hip replacement J Vasc Surg. 30 813 820 10550178 10.1016/S0741-5214(99)70005-4 1:STN:280:DC%2BD3c%2FhvVaqtw%3D%3D (Pubitemid 29534178)
7. G D'Andrea RL D'Ambrosio P Di Perna M Chetta R Santacroce V Brancaccio E Grandone M Margaglione 2005 A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin Blood. 105 645 649 15358623 10.1182/blood-2004-06-2111 (Pubitemid 40070748)
8. FDA News: August 16, 2007. Available at: www.fda.gov/bbs/topics/NEWS/ 2007/NEW01684.html. Accessed August 12, 2008.
9. A Fregin S Rost W Wolz A Krebsova CR Muller J Oldenburg 2002 Homozygosity mapping of a second gene locus for hereditary combined deficiency of vitamin K-dependent clotting factors to the centromeric region of chromosome 16 Blood. 100 3229 3232 12384421 10.1182/blood-2002-03-0698 1:CAS:528:DC%2BD38XosVSisbw%3D (Pubitemid 35217071)
10. RJ Friedman 2007 Optimal duration of prophylaxis for venous thromboembolism following total hip arthroplasty and total knee arthroplasty J Am Acad Orthop Surg. 15 148 155 17341671
11. WH Geerts GF Pineo JA Heit D Bergqvist MR Lassen CW Colwell JG Ray 2004 Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 3 338S 400S 15383478 10.1378/chest.126.3-suppl.338S 1:CAS:528:DC%2BD2cXptV2msbw%3D (Pubitemid 39302602)
12. A Gonzalez Della Valle A Serota G Sorriaux G Go N Sharrock TP Sculco E Salvati 2006 Venous thromboembolism is rare after total hip arthroplasty with a multimodal prophylaxis protocol Clin Orthop Relat Res. 443 146 153 10.1097/01.blo.0000201157.29325.f0 (Pubitemid 44616848)
13. Goodman LS, Gilman A, Brunton JS, Lazo JS, Parker KL. Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York, NY: McGraw-Hill; 2006.
14. DJ Greenblatt LL von Moltke 2005 Interaction of warfarin with drugs, natural substances, and foods J Clin Pharmacol. 45 127 132 15647404 10.1177/0091270004271404 1:CAS:528:DC%2BD2MXksFyhtrk%3D (Pubitemid 40490435)
15. DJ Harrington S Underwood C Morse MJ Shearer EG Tuddenham AD Mumford 2005 Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1 Thromb Haemost. 93 23 26 15630486 1:CAS:528:DC%2BD2MXptVyguw%3D%3D
16. TF Imperiale T Speroff 1994 A meta-analysis of methods to prevent venous thromboembolism following total hip replacement JAMA. 271 1780 1785 7515115 10.1001/jama.271.22.1780 1:STN:280:DyaK2c3lsVWksQ%3D%3D (Pubitemid 24166618)
17. CS Landefeld RJ Beyth 1993 Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention Am J Med. 95 315 328 8368229 10.1016/0002-9343(93)90285-W 1:STN:280:DyaK3sznslKruw%3D%3D (Pubitemid 23270290)
18. T Li LA Lange X Li L Susswein B Bryant R Malone EM Lange TY Huang DW Stafford JP Evans 2006 Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation J Med Genet. 43 740 744 16611750 10.1136/jmg.2005.040410 1:CAS:528:DC%2BD28XhtFGrtL7N (Pubitemid 44483917)
19. JR Lieberman R Sung F Dorey BJ Thomas DJ Kilgus GA Finerman 1997 Low-dose warfarin prophylaxis to prevent symptomatic pulmonary embolism after total knee arthroplasty J Arthroplasty. 12 180 184 9139100 10.1016/S0883-5403(97)90064-4 1:STN:280:DyaK2s3gsF2qsg%3D%3D (Pubitemid 27108289)
20. JR Lieberman J Wollaeger F Dorey BJ Thomas DJ Kilgus MJ Grecula GA Finerman HC Amstutz 1997 The efficacy of prophylaxis with low-dose warfarin for prevention of pulmonary embolism following total hip arthroplasty J Bone Joint Surg Am. 79 319 325 9070518 1:STN:280:DyaK2s3itl2gtQ%3D%3D (Pubitemid 27136639)
21. Memtsoudis SG, Gonzalez Della Valle A, Besculides MC, Gaber L, Laskin R. Trends in demographics, comorbidity profiles, in-hospital complications and mortality associated with primary knee arthroplasty 3 830 420 hospital discharges in the United States between 1990 and 2004. J Arthroplasty. 2008 April 14. [Epub ahead of print]
22. JW Mesko RA Brand R Iorio I Gradisar R Heekin R Leighton R Thornberry 2001 Venous thromboembolic disease management patterns in total hip arthroplasty and total knee arthroplasty patients: a survey of the AAHKS membership J Arthroplasty. 16 679 688 11547365 10.1054/arth.2001.25506 1:STN:280: DC%2BD3MvpvVWktw%3D%3D (Pubitemid 32803634)
23. M Messieh Z Huang LJ Johnson S Jobin 1999 Warfarin responses in total joint and hip fracture patients J Arthroplasty. 14 724 729 10512445 10.1016/S0883-5403(99)90228-0 1:STN:280:DyaK1MvktV2qtQ%3D%3D (Pubitemid 29448788)
24. E Millican PA Jacobsen-Lenzini PE Milligan L Grosso C Eby E Deych G Grice JC Clohisy RL Barrack RS Burnett D Voora S Gatchel A Tiemeier BF Gage 2007 Genetic-based dosing in orthopaedic patients beginning warfarin therapy Blood. 110 1511 1515 17387222 10.1182/blood-2007-01-069609 1:CAS:528:DC%2BD2sXhtVSgsb3N (Pubitemid 47443966)
25. J Miyagi N Funabashi M Suzuki M Asano T Kuriyama I Komuro H Moriya 2007 Predictive indicators of deep venous thrombosis and pulmonary arterial thromboembolism in 54 subjects after total knee arthroplasty using multislice computed tomography in logistic regression models Int J Cardiol. 119 90 94 17045675 10.1016/j.ijcard.2006.07.056 (Pubitemid 46818477)
26. KM Momary NL Shapiro MA Viana EA Nutescu CM Helgason LH Cavallari 2007 Factors influencing warfarin dose requirements in African-Americans Pharmacogenomics. 8 1535 1544 18034618 10.2217/14622416.8.11.1535 1:CAS:528:DC%2BD1cXntlegtg%3D%3D (Pubitemid 350286397)
27. P Paavolainen E Pukkala P Pulkkinen T Visuri 2002 Causes of death after total hip arthroplasty: a nationwide cohort study with 24, 638 patients J Arthroplasty. 17 274 281 11938501 10.1054/arth.2002.30774 (Pubitemid 34289999)
28. GD Paiement SJ Wessinger R Hughes WH Harris 1993 Routine use of adjusted low-dose warfarin to prevent venous thromboembolism after total hip replacement J Bone Joint Surg Am. 75 893 898 8314829 1:STN:280:DyaK3szgtVyrsw%3D%3D
29. VP Patel M Walsh B Sehgal C Preston H DeWal PE Di Cesare 2007 Factors associated with prolonged wound drainage after primary total hip and knee arthroplasty J Bone Joint Surg Am. 89 33 38 17200307 10.2106/JBJS.F.00163 (Pubitemid 46059142)
30. L Quteineh C Verstuyft C Descot L Dubert A Robert P Jaillon L Becquemont 2005 Vitamin K epoxide reductase (VKORC1) genetic polymorphism is associated to oral anticoagulant overdose Thromb Haemost. 94 690 691 16268497 1:CAS:528:DC%2BD2MXhtVaqurjK
31. PH Reitsma 2000 Genetic heterogeneity in hereditary thrombophilia Haemostasis. 30 1 10 11251335 1:CAS:528:DC%2BD3MXjtVygurg%3D
32. Reitsma PH, van der Heijden JF, Groot AP, Rosendaal FR, Buller HR. A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med. 2005;2:e312.
33. MJ Rieder AP Reiner BF Gage DA Nickerson CS Eby HL McLeod DK Blough KE Thummel DL Veenstra AE Rettie 2005 Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose N Engl J Med. 352 2285 2293 15930419 10.1056/NEJMoa044503 1:CAS:528:DC%2BD2MXksl2ltrk%3D (Pubitemid 40740552)
34. S Rost A Fregin M Hunerberg CG Bevans CR Muller J Oldenburg 2005 Site-directed mutagenesis of coumarin-type anticoagulant-sensitive VKORC1: evidence that highly conserved amino acids define structural requirements for enzymatic activity and inhibition by warfarin Thromb Haemost. 94 780 786 16270630
35. S Rost A Fregin V Ivaskevicius E Conzelmann K Hortnagel HJ Pelz K Lappegard E Seifried I Scharrer EG Tuddenham CR Muller TM Strom J Oldenburg 2004 Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2 Nature. 427 537 541 14765194 10.1038/nature02214 1:CAS:528:DC%2BD2cXpsFWhtQ%3D%3D (Pubitemid 38209110)
36. RA Sachs JH Smith M Kuney L Paxton 2003 Does anticoagulation do more harm than good? A comparison of patients treated without prophylaxis and patients treated with low-dose warfarin after total knee arthroplasty J Arthroplasty. 18 389 395 12820078 10.1016/S0883-5403(03)00071-8 (Pubitemid 36750106)
37. EA Salvati NE Sharrock G Westrich HG Potter A Gonzalez Della Valle TP Sculco 2007 The 2007 ABJS Nicolas Andry Award: three decades of clinical, basic, and applied research on thromboembolic disease after THA: rationale and clinical results of a multimodal prophylaxis protocol Clin Orthop Relat Res. 459 246 254 17545765 10.1097/BLO.0b013e31805b7681 (Pubitemid 46878224)
38. J Sanchez-Ballester M Smith K Hassan S Kershaw CS Elsworth L Jacobs 2005 Wound infection in the management of hip fractures: a comparison between low-molecular weight heparin and mechanical prophylaxis Acta Orthop Belg. 71 55 59 15792208
39. EA Sconce TI Khan HA Wynne P Avery L Monkhouse BP King P Wood P Kesteven AK Daly F Kamali 2005 The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen Blood. 106 2329 2333 15947090 10.1182/blood-2005-03-1108 1:CAS:528:DC%2BD2MXhtVKqt7%2FL (Pubitemid 41510803)
40. NE Sharrock G Go PC Harpel CS Ranawat TP Sculco EA Salvati 1995 The John Charnley Award Thrombogenesis during total hip arthroplasty. Clin Orthop Relat Res. 319 16 27
41. M Wadelius LY Chen K Downes J Ghori S Hunt N Eriksson O Wallerman H Melhus C Wadelius D Bentley P Deloukas 2005 Common VKORC1 and GGCX polymorphisms associated with warfarin dose Pharmacogenomics J. 5 262 270 15883587 10.1038/sj.tpj.6500313 1:CAS:528:DC%2BD2MXmsVyjs78%3D (Pubitemid 41131718)
42. AH Wu 2007 Use of genetic and nongenetic factors in warfarin dosing algorithms Pharmacogenomics. 8 851 861 18240910 10.2217/14622416.8.7.851 1:CAS:528:DC%2BD2sXnvVersLY%3D (Pubitemid 47288981)
43. HY Yuan JJ Chen MT Lee JC Wung YF Chen MJ Charng MJ Lu CR Hung CY Wei CH Chen JY Wu YT Chen 2005 A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity Hum Mol Genet. 14 1745 1751 15888487 10.1093/hmg/ddi180 1:CAS:528:DC%2BD2MXmvV2htL0%3D (Pubitemid 41430097)